Global Hematopoietic Stem Cell Transplantation Market research

Hematopoietic Stem Cell Transplantation Comprehensive Study by Type (Allogeneic, Autologous), Application (Peripheral Blood Stem Cells Transplant (PBSCT), Bone Marrow Transplant (BMT), Cord Blood Transplant (CBT)), Type of Disease (Solid tumors, Leukemia, Non-malignant disorders, Lymphoproliferative disorders), Therapeutic Application (AML (Acute Myeloid Leukemia), ALL (Acute Leukocyte Leukemia), HL (Hodgkin Leukemia), CML (Chronic Myeloid Leukemia), Others), End user (Hospitals, Speciality Centers), Source (Bone marrow, Peripheral blood stem cells, Umbilical cord blood) Players and Region - Global Market Outlook to 2030

Hematopoietic Stem Cell Transplantation Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 11.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Despite the increasing availability of smart antineoplastic therapies in recent years, Hematopoietic stem cell transplantation (HSCT) remains an optimal treatment modality for many hematologic malignancies. HSCT is one of a range of therapeutic options which is available to patients suffering from various diseases. It is a widely accepted treatment for many life-threatening diseases. The treatment is available to patients who suffer from refractory or relapsing neoplastic disease and non-neoplastic genetic disorders, as well as from chronic bone marrow failure. Hematopoietic stem cells are young or immature blood cells which are found to be living in bone marrow. These blood cells when matures in bone marrow very few enters into bloodstream. These cells that enter bloodstream are called as peripheral blood stems cells. Hematopoietic stem cells transplantation is the replacement of absent, diseased or damaged hematopoietic stem cells due to chemotherapy or radiation, with healthy hematopoietic stem cells.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledGilead Sciences Inc. (United States), Thermo Fisher Scientific (United States), PromoCell (Germany), CellGenix Technologie Transfer GmbH (Germany), Cesca Therapeutics Inc.(United States), R&D Systems (United States), Genlantis (United States), Lonza Group Ltd.(Switzerland), TiGenix N.V.(Belgium), ScienCell Research Laboratories (United States), Regen Biopharma Inc. (United States), China Cord Blood Corp (Hong Kong) and CBR Systems Inc. (United States)


According to AMA, the market for Hematopoietic Stem Cell Transplantation is expected to register a CAGR of 11.7% during the forecast period to 2030. This growth is primarily driven by Increasing prevalence of lymphoproliferative disorders like leukemia are expected to assist HSCs transplantation as survival rates in leukemia patient, Rising disposable income and demand for better treatment options, Rising awareness about healthcare infrastructure and Alternative treatment for relief from chemotherapy, radiotherapy and immune sensitive malignancy..

Globally, a noticeable market trend is evident Rising government support by providing a favorable environment for research laboratories The Life Sciences Tools & Services sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Gilead Sciences Inc. (United States), Thermo Fisher Scientific (United States), PromoCell (Germany), CellGenix Technologie Transfer GmbH (Germany), Cesca Therapeutics Inc.(United States), R&D Systems (United States), Genlantis (United States), Lonza Group Ltd.(Switzerland), TiGenix N.V.(Belgium), ScienCell Research Laboratories (United States), Regen Biopharma Inc. (United States), China Cord Blood Corp (Hong Kong) and CBR Systems Inc. (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The hematopoietic stem cells transplantation market appears to be diversified and competitive comprising of large number of players. The market is dominated by several players who are depending on their major competencies. The market is competing based on factors such as inorganic strategies, competitive pricing model, and expansion of HSC collection centers.

Key Developments in the Market:
On February 10, 2021, Fred Hutchinson Cancer Research Center and Takeda Pharmaceutical Company Announce Collaboration to Develop Next-Generation Cellular Therapies for Hematologic Malignancies
In January 2022, Fred Hutchinson Cancer Research Center Announces New Clinical Trial to Evaluate Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation (RIC HSCT) as a Treatment for Patients with High-Risk Myelodysplastic Syndromes (MDS)

Influencing Trend:
Rising government support by providing a favorable environment for research laboratories and The market has the potential in near future as being a perfect alternative to the traditional system in many congenital and acquired hematopoietic disorders management.

Market Growth Drivers:
Increasing prevalence of lymphoproliferative disorders like leukemia are expected to assist HSCs transplantation as survival rates in leukemia patient, Rising disposable income and demand for better treatment options, Rising awareness about healthcare infrastructure and Alternative treatment for relief from chemotherapy, radiotherapy and immune sensitive malignancy.

Challenges:
Ethical and legal challenges for HSCTis posing a challenge which is faced by the market

Restraints:
Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow to overcome the full potential of HSCT and They also face major barriers in expanding the use of HSCT beyond the replacement of immune and blood cells.

Opportunities:
Regenerative Stromal cell therapy is providing opportunity for the market as it considered as one of the major novel therapies for prevention and treatment for allogenic HSCT.

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Hematopoietic Stem Cell Transplantation Market
- Analysis about New Entrants in Hematopoietic Stem Cell Transplantation Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Hematopoietic Stem Cell Transplantation Study Sheds Light on
— The Hematopoietic Stem Cell Transplantation Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Hematopoietic Stem Cell Transplantation industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Hematopoietic Stem Cell Transplantation industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Allogeneic
  • Autologous
By Application
  • Peripheral Blood Stem Cells Transplant (PBSCT)
  • Bone Marrow Transplant (BMT)
  • Cord Blood Transplant (CBT)
By Type of Disease
  • Solid tumors
  • Leukemia
  • Non-malignant disorders
  • Lymphoproliferative disorders

By Therapeutic Application
  • AML (Acute Myeloid Leukemia)
  • ALL (Acute Leukocyte Leukemia)
  • HL (Hodgkin Leukemia)
  • CML (Chronic Myeloid Leukemia)
  • Others

By End user
  • Hospitals
  • Speciality Centers

By Source
  • Bone marrow
  • Peripheral blood stem cells
  • Umbilical cord blood

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing prevalence of lymphoproliferative disorders like leukemia are expected to assist HSCs transplantation as survival rates in leukemia patient
      • 3.2.2. Rising disposable income and demand for better treatment options
      • 3.2.3. Rising awareness about healthcare infrastructure
      • 3.2.4. Alternative treatment for relief from chemotherapy, radiotherapy and immune sensitive malignancy.
    • 3.3. Market Challenges
      • 3.3.1. Ethical and legal challenges for HSCTis posing a challenge which is faced by the market
    • 3.4. Market Trends
      • 3.4.1. Rising government support by providing a favorable environment for research laboratories
      • 3.4.2. The market has the potential in near future as being a perfect alternative to the traditional system in many congenital and acquired hematopoietic disorders management.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hematopoietic Stem Cell Transplantation, by Type, Application, Type of Disease, Therapeutic Application, End user, Source and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hematopoietic Stem Cell Transplantation (Value)
      • 5.2.1. Global Hematopoietic Stem Cell Transplantation by: Type (Value)
        • 5.2.1.1. Allogeneic
        • 5.2.1.2. Autologous
      • 5.2.2. Global Hematopoietic Stem Cell Transplantation by: Application (Value)
        • 5.2.2.1. Peripheral Blood Stem Cells Transplant (PBSCT)
        • 5.2.2.2. Bone Marrow Transplant (BMT)
        • 5.2.2.3. Cord Blood Transplant (CBT)
      • 5.2.3. Global Hematopoietic Stem Cell Transplantation by: Type of Disease (Value)
        • 5.2.3.1. Solid tumors
        • 5.2.3.2. Leukemia
        • 5.2.3.3. Non-malignant disorders
        • 5.2.3.4. Lymphoproliferative disorders
      • 5.2.4. Global Hematopoietic Stem Cell Transplantation by: Therapeutic Application (Value)
        • 5.2.4.1. AML (Acute Myeloid Leukemia)
        • 5.2.4.2. ALL (Acute Leukocyte Leukemia)
        • 5.2.4.3. HL (Hodgkin Leukemia)
        • 5.2.4.4. CML (Chronic Myeloid Leukemia)
        • 5.2.4.5. Others
      • 5.2.5. Global Hematopoietic Stem Cell Transplantation by: End user (Value)
        • 5.2.5.1. Hospitals
        • 5.2.5.2. Speciality Centers
      • 5.2.6. Global Hematopoietic Stem Cell Transplantation by: Source (Value)
        • 5.2.6.1. Bone marrow
        • 5.2.6.2. Peripheral blood stem cells
        • 5.2.6.3. Umbilical cord blood
      • 5.2.7. Global Hematopoietic Stem Cell Transplantation Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
  • 6. Hematopoietic Stem Cell Transplantation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gilead Sciences Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. PromoCell (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. CellGenix Technologie Transfer GmbH (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Cesca Therapeutics Inc.(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. R&D Systems (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Genlantis (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lonza Group Ltd.(Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. TiGenix N.V.(Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. ScienCell Research Laboratories (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Regen Biopharma Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. China Cord Blood Corp (Hong Kong)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. CBR Systems Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Hematopoietic Stem Cell Transplantation Sale, by Type, Application, Type of Disease, Therapeutic Application, End user, Source and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hematopoietic Stem Cell Transplantation (Value)
      • 7.2.1. Global Hematopoietic Stem Cell Transplantation by: Type (Value)
        • 7.2.1.1. Allogeneic
        • 7.2.1.2. Autologous
      • 7.2.2. Global Hematopoietic Stem Cell Transplantation by: Application (Value)
        • 7.2.2.1. Peripheral Blood Stem Cells Transplant (PBSCT)
        • 7.2.2.2. Bone Marrow Transplant (BMT)
        • 7.2.2.3. Cord Blood Transplant (CBT)
      • 7.2.3. Global Hematopoietic Stem Cell Transplantation by: Type of Disease (Value)
        • 7.2.3.1. Solid tumors
        • 7.2.3.2. Leukemia
        • 7.2.3.3. Non-malignant disorders
        • 7.2.3.4. Lymphoproliferative disorders
      • 7.2.4. Global Hematopoietic Stem Cell Transplantation by: Therapeutic Application (Value)
        • 7.2.4.1. AML (Acute Myeloid Leukemia)
        • 7.2.4.2. ALL (Acute Leukocyte Leukemia)
        • 7.2.4.3. HL (Hodgkin Leukemia)
        • 7.2.4.4. CML (Chronic Myeloid Leukemia)
        • 7.2.4.5. Others
      • 7.2.5. Global Hematopoietic Stem Cell Transplantation by: End user (Value)
        • 7.2.5.1. Hospitals
        • 7.2.5.2. Speciality Centers
      • 7.2.6. Global Hematopoietic Stem Cell Transplantation by: Source (Value)
        • 7.2.6.1. Bone marrow
        • 7.2.6.2. Peripheral blood stem cells
        • 7.2.6.3. Umbilical cord blood
      • 7.2.7. Global Hematopoietic Stem Cell Transplantation Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hematopoietic Stem Cell Transplantation: by Type(USD Million)
  • Table 2. Hematopoietic Stem Cell Transplantation Allogeneic , by Region USD Million (2018-2023)
  • Table 3. Hematopoietic Stem Cell Transplantation Autologous , by Region USD Million (2018-2023)
  • Table 4. Hematopoietic Stem Cell Transplantation: by Application(USD Million)
  • Table 5. Hematopoietic Stem Cell Transplantation Peripheral Blood Stem Cells Transplant (PBSCT) , by Region USD Million (2018-2023)
  • Table 6. Hematopoietic Stem Cell Transplantation Bone Marrow Transplant (BMT) , by Region USD Million (2018-2023)
  • Table 7. Hematopoietic Stem Cell Transplantation Cord Blood Transplant (CBT) , by Region USD Million (2018-2023)
  • Table 8. Hematopoietic Stem Cell Transplantation: by Type of Disease(USD Million)
  • Table 9. Hematopoietic Stem Cell Transplantation Solid tumors , by Region USD Million (2018-2023)
  • Table 10. Hematopoietic Stem Cell Transplantation Leukemia , by Region USD Million (2018-2023)
  • Table 11. Hematopoietic Stem Cell Transplantation Non-malignant disorders , by Region USD Million (2018-2023)
  • Table 12. Hematopoietic Stem Cell Transplantation Lymphoproliferative disorders , by Region USD Million (2018-2023)
  • Table 13. Hematopoietic Stem Cell Transplantation: by Therapeutic Application(USD Million)
  • Table 14. Hematopoietic Stem Cell Transplantation AML (Acute Myeloid Leukemia) , by Region USD Million (2018-2023)
  • Table 15. Hematopoietic Stem Cell Transplantation ALL (Acute Leukocyte Leukemia) , by Region USD Million (2018-2023)
  • Table 16. Hematopoietic Stem Cell Transplantation HL (Hodgkin Leukemia) , by Region USD Million (2018-2023)
  • Table 17. Hematopoietic Stem Cell Transplantation CML (Chronic Myeloid Leukemia) , by Region USD Million (2018-2023)
  • Table 18. Hematopoietic Stem Cell Transplantation Others , by Region USD Million (2018-2023)
  • Table 19. Hematopoietic Stem Cell Transplantation: by End user(USD Million)
  • Table 20. Hematopoietic Stem Cell Transplantation Hospitals , by Region USD Million (2018-2023)
  • Table 21. Hematopoietic Stem Cell Transplantation Speciality Centers , by Region USD Million (2018-2023)
  • Table 22. Hematopoietic Stem Cell Transplantation: by Source(USD Million)
  • Table 23. Hematopoietic Stem Cell Transplantation Bone marrow , by Region USD Million (2018-2023)
  • Table 24. Hematopoietic Stem Cell Transplantation Peripheral blood stem cells , by Region USD Million (2018-2023)
  • Table 25. Hematopoietic Stem Cell Transplantation Umbilical cord blood , by Region USD Million (2018-2023)
  • Table 26. South America Hematopoietic Stem Cell Transplantation, by Country USD Million (2018-2023)
  • Table 27. South America Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 28. South America Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 29. South America Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 30. South America Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 31. South America Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 32. South America Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 33. Brazil Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 34. Brazil Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 35. Brazil Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 36. Brazil Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 37. Brazil Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 38. Brazil Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 39. Argentina Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 40. Argentina Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 41. Argentina Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 42. Argentina Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 43. Argentina Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 44. Argentina Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 45. Rest of South America Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 46. Rest of South America Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 47. Rest of South America Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 48. Rest of South America Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 49. Rest of South America Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 50. Rest of South America Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 51. Asia Pacific Hematopoietic Stem Cell Transplantation, by Country USD Million (2018-2023)
  • Table 52. Asia Pacific Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 53. Asia Pacific Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 54. Asia Pacific Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 55. Asia Pacific Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 56. Asia Pacific Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 57. Asia Pacific Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 58. China Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 59. China Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 60. China Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 61. China Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 62. China Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 63. China Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 64. Japan Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 65. Japan Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 66. Japan Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 67. Japan Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 68. Japan Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 69. Japan Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 70. India Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 71. India Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 72. India Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 73. India Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 74. India Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 75. India Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 76. South Korea Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 77. South Korea Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 78. South Korea Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 79. South Korea Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 80. South Korea Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 81. South Korea Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 82. Taiwan Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 83. Taiwan Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 84. Taiwan Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 85. Taiwan Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 86. Taiwan Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 87. Taiwan Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 88. Australia Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 89. Australia Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 90. Australia Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 91. Australia Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 92. Australia Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 93. Australia Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 94. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 95. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 96. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 97. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 98. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 99. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 100. Europe Hematopoietic Stem Cell Transplantation, by Country USD Million (2018-2023)
  • Table 101. Europe Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 102. Europe Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 103. Europe Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 104. Europe Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 105. Europe Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 106. Europe Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 107. Germany Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 108. Germany Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 109. Germany Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 110. Germany Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 111. Germany Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 112. Germany Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 113. France Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 114. France Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 115. France Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 116. France Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 117. France Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 118. France Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 119. Italy Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 120. Italy Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 121. Italy Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 122. Italy Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 123. Italy Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 124. Italy Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 125. United Kingdom Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 126. United Kingdom Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 127. United Kingdom Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 128. United Kingdom Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 129. United Kingdom Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 130. United Kingdom Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 131. Netherlands Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 132. Netherlands Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 133. Netherlands Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 134. Netherlands Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 135. Netherlands Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 136. Netherlands Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 137. Rest of Europe Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 138. Rest of Europe Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 139. Rest of Europe Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 140. Rest of Europe Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 141. Rest of Europe Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 142. Rest of Europe Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 143. MEA Hematopoietic Stem Cell Transplantation, by Country USD Million (2018-2023)
  • Table 144. MEA Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 145. MEA Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 146. MEA Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 147. MEA Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 148. MEA Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 149. MEA Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 150. Middle East Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 151. Middle East Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 152. Middle East Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 153. Middle East Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 154. Middle East Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 155. Middle East Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 156. Africa Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 157. Africa Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 158. Africa Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 159. Africa Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 160. Africa Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 161. Africa Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 162. North America Hematopoietic Stem Cell Transplantation, by Country USD Million (2018-2023)
  • Table 163. North America Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 164. North America Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 165. North America Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 166. North America Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 167. North America Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 168. North America Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 169. United States Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 170. United States Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 171. United States Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 172. United States Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 173. United States Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 174. United States Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 175. Canada Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 176. Canada Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 177. Canada Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 178. Canada Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 179. Canada Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 180. Canada Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 181. Mexico Hematopoietic Stem Cell Transplantation, by Type USD Million (2018-2023)
  • Table 182. Mexico Hematopoietic Stem Cell Transplantation, by Application USD Million (2018-2023)
  • Table 183. Mexico Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2018-2023)
  • Table 184. Mexico Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2018-2023)
  • Table 185. Mexico Hematopoietic Stem Cell Transplantation, by End user USD Million (2018-2023)
  • Table 186. Mexico Hematopoietic Stem Cell Transplantation, by Source USD Million (2018-2023)
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Hematopoietic Stem Cell Transplantation: by Type(USD Million)
  • Table 201. Hematopoietic Stem Cell Transplantation Allogeneic , by Region USD Million (2025-2030)
  • Table 202. Hematopoietic Stem Cell Transplantation Autologous , by Region USD Million (2025-2030)
  • Table 203. Hematopoietic Stem Cell Transplantation: by Application(USD Million)
  • Table 204. Hematopoietic Stem Cell Transplantation Peripheral Blood Stem Cells Transplant (PBSCT) , by Region USD Million (2025-2030)
  • Table 205. Hematopoietic Stem Cell Transplantation Bone Marrow Transplant (BMT) , by Region USD Million (2025-2030)
  • Table 206. Hematopoietic Stem Cell Transplantation Cord Blood Transplant (CBT) , by Region USD Million (2025-2030)
  • Table 207. Hematopoietic Stem Cell Transplantation: by Type of Disease(USD Million)
  • Table 208. Hematopoietic Stem Cell Transplantation Solid tumors , by Region USD Million (2025-2030)
  • Table 209. Hematopoietic Stem Cell Transplantation Leukemia , by Region USD Million (2025-2030)
  • Table 210. Hematopoietic Stem Cell Transplantation Non-malignant disorders , by Region USD Million (2025-2030)
  • Table 211. Hematopoietic Stem Cell Transplantation Lymphoproliferative disorders , by Region USD Million (2025-2030)
  • Table 212. Hematopoietic Stem Cell Transplantation: by Therapeutic Application(USD Million)
  • Table 213. Hematopoietic Stem Cell Transplantation AML (Acute Myeloid Leukemia) , by Region USD Million (2025-2030)
  • Table 214. Hematopoietic Stem Cell Transplantation ALL (Acute Leukocyte Leukemia) , by Region USD Million (2025-2030)
  • Table 215. Hematopoietic Stem Cell Transplantation HL (Hodgkin Leukemia) , by Region USD Million (2025-2030)
  • Table 216. Hematopoietic Stem Cell Transplantation CML (Chronic Myeloid Leukemia) , by Region USD Million (2025-2030)
  • Table 217. Hematopoietic Stem Cell Transplantation Others , by Region USD Million (2025-2030)
  • Table 218. Hematopoietic Stem Cell Transplantation: by End user(USD Million)
  • Table 219. Hematopoietic Stem Cell Transplantation Hospitals , by Region USD Million (2025-2030)
  • Table 220. Hematopoietic Stem Cell Transplantation Speciality Centers , by Region USD Million (2025-2030)
  • Table 221. Hematopoietic Stem Cell Transplantation: by Source(USD Million)
  • Table 222. Hematopoietic Stem Cell Transplantation Bone marrow , by Region USD Million (2025-2030)
  • Table 223. Hematopoietic Stem Cell Transplantation Peripheral blood stem cells , by Region USD Million (2025-2030)
  • Table 224. Hematopoietic Stem Cell Transplantation Umbilical cord blood , by Region USD Million (2025-2030)
  • Table 225. South America Hematopoietic Stem Cell Transplantation, by Country USD Million (2025-2030)
  • Table 226. South America Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 227. South America Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 228. South America Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 229. South America Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 230. South America Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 231. South America Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 232. Brazil Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 233. Brazil Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 234. Brazil Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 235. Brazil Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 236. Brazil Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 237. Brazil Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 238. Argentina Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 239. Argentina Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 240. Argentina Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 241. Argentina Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 242. Argentina Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 243. Argentina Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 244. Rest of South America Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 245. Rest of South America Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 246. Rest of South America Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 247. Rest of South America Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 248. Rest of South America Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 249. Rest of South America Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 250. Asia Pacific Hematopoietic Stem Cell Transplantation, by Country USD Million (2025-2030)
  • Table 251. Asia Pacific Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 252. Asia Pacific Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 253. Asia Pacific Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 254. Asia Pacific Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 255. Asia Pacific Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 256. Asia Pacific Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 257. China Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 258. China Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 259. China Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 260. China Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 261. China Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 262. China Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 263. Japan Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 264. Japan Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 265. Japan Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 266. Japan Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 267. Japan Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 268. Japan Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 269. India Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 270. India Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 271. India Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 272. India Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 273. India Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 274. India Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 275. South Korea Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 276. South Korea Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 277. South Korea Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 278. South Korea Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 279. South Korea Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 280. South Korea Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 281. Taiwan Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 282. Taiwan Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 283. Taiwan Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 284. Taiwan Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 285. Taiwan Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 286. Taiwan Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 287. Australia Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 288. Australia Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 289. Australia Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 290. Australia Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 291. Australia Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 292. Australia Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 293. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 294. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 295. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 296. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 297. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 298. Rest of Asia-Pacific Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 299. Europe Hematopoietic Stem Cell Transplantation, by Country USD Million (2025-2030)
  • Table 300. Europe Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 301. Europe Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 302. Europe Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 303. Europe Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 304. Europe Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 305. Europe Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 306. Germany Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 307. Germany Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 308. Germany Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 309. Germany Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 310. Germany Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 311. Germany Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 312. France Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 313. France Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 314. France Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 315. France Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 316. France Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 317. France Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 318. Italy Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 319. Italy Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 320. Italy Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 321. Italy Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 322. Italy Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 323. Italy Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 324. United Kingdom Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 325. United Kingdom Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 326. United Kingdom Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 327. United Kingdom Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 328. United Kingdom Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 329. United Kingdom Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 330. Netherlands Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 331. Netherlands Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 332. Netherlands Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 333. Netherlands Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 334. Netherlands Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 335. Netherlands Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 336. Rest of Europe Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 337. Rest of Europe Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 338. Rest of Europe Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 339. Rest of Europe Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 340. Rest of Europe Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 341. Rest of Europe Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 342. MEA Hematopoietic Stem Cell Transplantation, by Country USD Million (2025-2030)
  • Table 343. MEA Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 344. MEA Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 345. MEA Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 346. MEA Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 347. MEA Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 348. MEA Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 349. Middle East Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 350. Middle East Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 351. Middle East Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 352. Middle East Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 353. Middle East Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 354. Middle East Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 355. Africa Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 356. Africa Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 357. Africa Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 358. Africa Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 359. Africa Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 360. Africa Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 361. North America Hematopoietic Stem Cell Transplantation, by Country USD Million (2025-2030)
  • Table 362. North America Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 363. North America Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 364. North America Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 365. North America Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 366. North America Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 367. North America Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 368. United States Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 369. United States Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 370. United States Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 371. United States Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 372. United States Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 373. United States Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 374. Canada Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 375. Canada Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 376. Canada Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 377. Canada Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 378. Canada Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 379. Canada Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 380. Mexico Hematopoietic Stem Cell Transplantation, by Type USD Million (2025-2030)
  • Table 381. Mexico Hematopoietic Stem Cell Transplantation, by Application USD Million (2025-2030)
  • Table 382. Mexico Hematopoietic Stem Cell Transplantation, by Type of Disease USD Million (2025-2030)
  • Table 383. Mexico Hematopoietic Stem Cell Transplantation, by Therapeutic Application USD Million (2025-2030)
  • Table 384. Mexico Hematopoietic Stem Cell Transplantation, by End user USD Million (2025-2030)
  • Table 385. Mexico Hematopoietic Stem Cell Transplantation, by Source USD Million (2025-2030)
  • Table 386. Research Programs/Design for This Report
  • Table 387. Key Data Information from Secondary Sources
  • Table 388. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hematopoietic Stem Cell Transplantation: by Type USD Million (2018-2023)
  • Figure 5. Global Hematopoietic Stem Cell Transplantation: by Application USD Million (2018-2023)
  • Figure 6. Global Hematopoietic Stem Cell Transplantation: by Type of Disease USD Million (2018-2023)
  • Figure 7. Global Hematopoietic Stem Cell Transplantation: by Therapeutic Application USD Million (2018-2023)
  • Figure 8. Global Hematopoietic Stem Cell Transplantation: by End user USD Million (2018-2023)
  • Figure 9. Global Hematopoietic Stem Cell Transplantation: by Source USD Million (2018-2023)
  • Figure 10. South America Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 11. Asia Pacific Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 12. Europe Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 13. MEA Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 14. North America Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 15. Global Hematopoietic Stem Cell Transplantation share by Players 2023 (%)
  • Figure 16. Global Hematopoietic Stem Cell Transplantation share by Players (Top 3) 2023(%)
  • Figure 17. Global Hematopoietic Stem Cell Transplantation share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Gilead Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Gilead Sciences Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 22. Thermo Fisher Scientific (United States) Revenue: by Geography 2023
  • Figure 23. PromoCell (Germany) Revenue, Net Income and Gross profit
  • Figure 24. PromoCell (Germany) Revenue: by Geography 2023
  • Figure 25. CellGenix Technologie Transfer GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 26. CellGenix Technologie Transfer GmbH (Germany) Revenue: by Geography 2023
  • Figure 27. Cesca Therapeutics Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 28. Cesca Therapeutics Inc.(United States) Revenue: by Geography 2023
  • Figure 29. R&D Systems (United States) Revenue, Net Income and Gross profit
  • Figure 30. R&D Systems (United States) Revenue: by Geography 2023
  • Figure 31. Genlantis (United States) Revenue, Net Income and Gross profit
  • Figure 32. Genlantis (United States) Revenue: by Geography 2023
  • Figure 33. Lonza Group Ltd.(Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Lonza Group Ltd.(Switzerland) Revenue: by Geography 2023
  • Figure 35. TiGenix N.V.(Belgium) Revenue, Net Income and Gross profit
  • Figure 36. TiGenix N.V.(Belgium) Revenue: by Geography 2023
  • Figure 37. ScienCell Research Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 38. ScienCell Research Laboratories (United States) Revenue: by Geography 2023
  • Figure 39. Regen Biopharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Regen Biopharma Inc. (United States) Revenue: by Geography 2023
  • Figure 41. China Cord Blood Corp (Hong Kong) Revenue, Net Income and Gross profit
  • Figure 42. China Cord Blood Corp (Hong Kong) Revenue: by Geography 2023
  • Figure 43. CBR Systems Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. CBR Systems Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Global Hematopoietic Stem Cell Transplantation: by Type USD Million (2025-2030)
  • Figure 46. Global Hematopoietic Stem Cell Transplantation: by Application USD Million (2025-2030)
  • Figure 47. Global Hematopoietic Stem Cell Transplantation: by Type of Disease USD Million (2025-2030)
  • Figure 48. Global Hematopoietic Stem Cell Transplantation: by Therapeutic Application USD Million (2025-2030)
  • Figure 49. Global Hematopoietic Stem Cell Transplantation: by End user USD Million (2025-2030)
  • Figure 50. Global Hematopoietic Stem Cell Transplantation: by Source USD Million (2025-2030)
  • Figure 51. South America Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 52. Asia Pacific Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 53. Europe Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 54. MEA Hematopoietic Stem Cell Transplantation Share (%), by Country
  • Figure 55. North America Hematopoietic Stem Cell Transplantation Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Gilead Sciences Inc. (United States)
  • Thermo Fisher Scientific (United States)
  • PromoCell (Germany)
  • CellGenix Technologie Transfer GmbH (Germany)
  • Cesca Therapeutics Inc.(United States)
  • R&D Systems (United States)
  • Genlantis (United States)
  • Lonza Group Ltd.(Switzerland)
  • TiGenix N.V.(Belgium)
  • ScienCell Research Laboratories (United States)
  • Regen Biopharma Inc. (United States)
  • China Cord Blood Corp (Hong Kong)
  • CBR Systems Inc. (United States)
Additional players considered in the study are as follows:
Escape Therapeutics Inc. (United States) , Cryo-Save AG (Germany) , Pluristem Therapeutics Inc. (Israel) , ViaCord Inc.(United States)
Select User Access Type

Key Highlights of Report


Mar 2024 248 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hematopoietic Stem Cell Transplantation Market research Quantitative research analysis
Global Hematopoietic Stem Cell Transplantation Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Hematopoietic Stem Cell Transplantation market are Gilead Sciences Inc. (United States), Thermo Fisher Scientific (United States), PromoCell (Germany), CellGenix Technologie Transfer GmbH (Germany), Cesca Therapeutics Inc.(United States), R&D Systems (United States), Genlantis (United States), Lonza Group Ltd.(Switzerland), TiGenix N.V.(Belgium), ScienCell Research Laboratories (United States), Regen Biopharma Inc. (United States), China Cord Blood Corp (Hong Kong) and CBR Systems Inc. (United States), to name a few.
North America is dominating the Hematopoietic Stem Cell Transplantation Market.
"Ethical and legal challenges for HSCTis posing a challenge which is faced by the market" is seen as one of the major challenges by many Industry Players of Hematopoietic Stem Cell Transplantation Market
The Hematopoietic Stem Cell Transplantation market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Hematopoietic Stem Cell Transplantation market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global Hematopoietic Stem Cell Transplantation Market research Report?

Have a Query? Click Here

Other Related Reports

Stem Cells Comprehensive Study by Type (Adult Stem Cells (Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others), Human Embryonic Stem Cells (hESC), Induced Pluripotent Stem Cells, Very Small ...
$ 3750
Viral Disease Diagnosis Comprehensive Study by Diagnostic Test (Serodiagnostic Tests, Specimen Examination, Viral Isolation), Virus (Dengue virus, Hepatitis virus, HIV-1, Human Metapneumovirus, Meas...
$ 3650
Molecular Weight Marker Comprehensive Study by Type (DNA Markers (Below 50 bp, 50 bp to 100 bp, 100 bp to 1 kb, 1 kb to 5 kb, Above 5 kb), Protein Markers (Below 10 kDa, 10 k Da to 100 kDa, 100 k Da ...
$ 3750
Life Science Instrumentation Comprehensive Study by Type (Spectroscopy, Chromatography, Flow Cytometry, NGS, PCR, Microscopy), Application (Clinical Application, Diagnostic Applications), End User (R...
$ 3450
PCR Reagent Comprehensive Study by Type (Primer, Enzyme, DNTP, Template, Buffer Solution), Application (Medical Care, Scientific Research, Others), End users (Research Centers and Academic & Governme...
$ 3650
Liquid Handling System Comprehensive Study by Type (Pipettes, Electronic, Manual, Semi-Automated, Consumables, Disposable Tips, Tubes & Plates, Reagent Containers, Other Consumables, Microplate Reage...
$ 3750